Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wegovy, Eli Lilly
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
2h
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
2d
on MSN
Why Is Eli Lilly and Company (LLY) Among Ken Fisher’s Top Stock Picks Heading Into 2025?
We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...
6d
on MSN
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...
6d
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Yahoo Finance
1d
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
Dave Ricks of
Eli
Lilly
is having a banner year. All that innovation, of course, is expensive, as we know, because drug
company
CEOs are often pilloried in the court of public opinion. But take ...
STAT
1d
Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves
Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.
23h
Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...
2d
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Zepbound
Wegovy
Novo Nordisk
Glucagon-like peptide-1
Feedback